SAN FRANCISCO and Suzhou, China, May 31, 2022 / PRNewswire / – Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality drugs for the treatment of oncology, autoimmune, metabolic, ophthalmic and other major diseases, today announced the appointment of Mr. Gary Cuckoo as an independent non-executive director of the Board of Directors (the “Board”) and a member of the Board’s Audit Committee and the Board’s Strategy Committee.
Mr. Zeziula has more than 40 years of experience building and leading strong, sustainable sales and operations organizations. Europe and North America in several MNCs. He is currently President of Kyowa Kirin USA Holdings, Inc. (“Kyowa Kirin USA“), the headquarters of the North American region of Kyowa Kirin Co., Ltd (” Kyowa Kirin “) (TSE: 4151). Kyowa Kirin is JapanA global specialized pharmaceutical company that applies cutting-edge science, including expertise in antibody research and technology, to meet the needs of patients in a variety of therapeutic areas, such as nephrology, oncology, immunology / allergy, and neurology. Mr. Zeziula joined Kyowa Kirin USA in 2019. Under his leadership North America has become the fastest growing region of world business Kyowa Kirin. Before joining Kyowa Kirin USAMr. Zieziula has consistently served as Chief Commercial Officer and President of EMD Serono, a North American subsidiary of the pharmaceutical company Merck KGaA, where he has contributed to the successful commercialization of the company’s cancer, nerve / immune, fertile and endocrine products. North America, reversed the downward trend of many products in the North American market and boosted market share growth. Previously, Mr. Zeziula served as a strategic advisor to venture capitalists and pharmaceutical companies on mergers and acquisitions and product licensing opportunities in the global pharmaceutical and biotechnology market. Mr. Zieziul also held important positions at AMAG, Roche, Bristol Myers Squibb and Merck & Co. Mr. Cuckoo received his bachelor’s degree New York State University and an MBA degree from Canis College.
Doctor Mikhail Yufounder, chairman and CEO of Innovent, stated:“We warmly welcome Mr. Zeziulu to join the Board of Directors of Innovent. Mr. Zeziula has extensive experience in managing the successful global commercialization of drugs in many major pharmaceutical and biotechnology companies, and has an in-depth understanding of global pipeline planning, evaluation, and promotion. Mr. Zeziula is a member of the Board during the critical period of Innovent’s development, which not only makes the Board more diversified, but also brings us additional experience of globalization. We believe that his participation will enable Innovent to develop strategic globalization plans that support the company in achieving our mission – to grow into a world-leading biopharmaceutical company and make Innovent’s innovative drugs benefit more global patients.“
Mr. Cuckoo, said: “I am honored to join the Innovent Board and look forward to working with such an innovative, professional and efficient team. Innovent is a young and promising company. Over the past decade, Innovent has successfully created a fully integrated research and development platform, CMC and commercialization, and also created global innovation opportunities for research and clinical development that lay a solid foundation for innovation and globalization in the next decade. I am honored to contribute to Innovent ‘s strategic goal and mission.
Inspired by the spirit of “Start with honesty, succeed through action”, Innovent’s mission is to develop, manufacture and commercialize high quality biopharmaceutical products available to ordinary people. Founded in 2011, Innovent is committed to developing, manufacturing and commercializing high quality innovative drugs for the treatment of cancer, autoimmune, metabolicophthalmology and other serious diseases. On October 31, 2018Innovent was listed on the main board of the Hong Kong Limited Stock Exchange with share code: 01801.HK.
Since its inception, Innovent has developed a fully integrated multifunctional platform that includes R&D, CMC (chemistry, manufacturing and control), clinical development and commercialization opportunities. Using the platform, the company has built a robust pipeline of 32 valuable assets in cancer, autoimmune, metabolic, ophthalmology and other major therapeutic areas, with 7 products approved for marketing in China – TYVYT® (synthilimab injection), BYVASDA® (biosimilar injections of bevacizumab), SULINNO® (biosimilar injections of adalimumab), HALPRYZA® (biosimilar injections of rituximab), Pemazyre® (oral and TABL) Bolvere) and Cyramza® (ramucirumab), 1 asset under the NDA NMPA review, 5 assets in phase 3 or major clinical trials and an additional 19 molecules in clinical trials.
Innovent has created an international team with cutting-edge talents in the development and commercialization of high-end biologicals, including many global experts. The company has also entered into strategic partnerships with Eli Lilly and Company, Adimab, Incyte, MD Anderson Cancer Center, Hanmi and other international partners. Innovent is committed to working with many employees to help advance Of China biopharmaceutical industry, increase drug availability and improve patients ’quality of life. For more information, visit: www.innoventbio.com. and www.linkedin.com/company/innovent-biologics/.
TYVYT® (syntilimab for injection) is not a permitted product USA.
BYVASDA® (biosimilar injections of bevacizumab), SULINNO® and HALPRYZA® (biosimilar injections of rituximab) are not permitted products in USA.
TYVYT® (synthilimab injection, Innovent)
BYVASDA® (biosimilar injections of bevacizumab, Innovent)
HALPRYZA® (biosimilar injections of rituximab, Innovent)
SULINNO® (biosimilar injections of adalimumab, Innovent)
Pemazir® (oral inhibitor of pemigatinib, Incyte Corporation). Pemazyre® was opened by Incyte Corporation and licensed by Innovent to develop and commercialize in China, Hong Kong, Macau and Taiwan.
CYRAMZA® (ramucirumab, Eli Lily). Cyramza® was opened by Eli Lilly and licensed by Innovent for commercialization in China.
Statements about the future
This news release may contain certain forward-looking statements that, by their nature, are subject to significant risks and uncertainties. The words “anticipate,” “believe,” “evaluate,” “expect,” “intend,” and similar expressions referring to Innovent Biologics, Inc. (“Innovent” or “Company”) is designed to identify some of such promising statements. The company does not intend to update these forward-looking statements on a regular basis.
These forward-looking statements are based on existing beliefs, assumptions, expectations, estimates, projections and the management’s understanding of future events at the time of making these statements. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the control of the company and are difficult to predict. Thus, actual results may differ materially from the information contained in forward-looking statements as a result of future changes or developments in our business, the company’s competitive environment, and the political, economic, legal, and social environment.
The Company, directors and employees of the company do not undertake (a) any obligation to correct or update the forward-looking statements contained on this site; and (b) no liability in the event that any of the forward-looking statements materialize or prove to be incorrect.
See original content for multimedia downloads:https://www.prnewswire.com/news-releases/innovent-appoints-mr-gary-zieziula-as-independent-non-executive-director-301558090.html
SOURCE Innovent Biologics